D-Index & Metrics Best Publications
Hubert Schrezenmeier

Hubert Schrezenmeier

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 76 Citations 20,186 333 World Ranking 11441 National Ranking 524

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Gene
  • Immune system

His primary areas of study are Immunology, Internal medicine, Surgery, Aplastic anemia and Anemia. His work deals with themes such as Cancer research, Mesenchymal stem cell and Stem cell, which intersect with Immunology. His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Endocrinology.

His Gastroenterology research includes elements of Hemolytic anemia, Hemoglobinuria and Eculizumab. His work carried out in the field of Aplastic anemia brings together such families of science as Bone marrow failure, Chemotherapy, Immunosuppression, Transplantation and Immunotherapy. His research in Anemia focuses on subjects like Bone marrow, which are connected to Cell adhesion molecule.

His most cited work include:

  • The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (845 citations)
  • Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. (417 citations)
  • Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. (391 citations)

What are the main themes of his work throughout his whole career to date?

His main research concerns Internal medicine, Immunology, Paroxysmal nocturnal hemoglobinuria, Aplastic anemia and Eculizumab. His Internal medicine research includes themes of Gastroenterology and Surgery. Hubert Schrezenmeier has included themes like Mesenchymal stem cell, Cancer research and Stem cell in his Immunology study.

The study incorporates disciplines such as Hemolytic anemia, Complement component 5, Hemoglobinuria and Pediatrics in addition to Paroxysmal nocturnal hemoglobinuria. Hubert Schrezenmeier combines subjects such as Immunosuppression, Bone marrow failure and Anemia with his study of Aplastic anemia. The Eculizumab study combines topics in areas such as Complement inhibitor, Hemolysis, Thrombosis and Lactate dehydrogenase.

He most often published in these fields:

  • Internal medicine (39.70%)
  • Immunology (35.57%)
  • Paroxysmal nocturnal hemoglobinuria (24.08%)

What were the highlights of his more recent work (between 2018-2021)?

  • Internal medicine (39.70%)
  • Paroxysmal nocturnal hemoglobinuria (24.08%)
  • Eculizumab (21.91%)

In recent papers he was focusing on the following fields of study:

Hubert Schrezenmeier mainly investigates Internal medicine, Paroxysmal nocturnal hemoglobinuria, Eculizumab, Immunology and Cell biology. His Internal medicine research incorporates themes from Gastroenterology, Human leukocyte antigen and Oncology. His work is dedicated to discovering how Gastroenterology, Confidence interval are connected with Clinical trial and other disciplines.

As a part of the same scientific study, Hubert Schrezenmeier usually deals with the Paroxysmal nocturnal hemoglobinuria, concentrating on Complement component 5 and frequently concerns with Tolerability and Surrogate endpoint. His Eculizumab study combines topics from a wide range of disciplines, such as Hemolysis, Hemoglobinuria, Thrombosis and Bone marrow failure. Hubert Schrezenmeier interconnects COMPLEMENT REGULATORS, Opsonin and Brown adipose tissue in the investigation of issues within Cell biology.

Between 2018 and 2021, his most popular works were:

  • Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study (84 citations)
  • Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study (84 citations)
  • Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation (66 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Gene
  • Immune system

His primary scientific interests are in Internal medicine, Eculizumab, Paroxysmal nocturnal hemoglobinuria, Complement system and Antibody. Internal medicine is frequently linked to Oncology in his study. His studies deal with areas such as Lectin pathway, Biallelic Mutation, Genomic imprinting and Cell biology as well as Eculizumab.

His Paroxysmal nocturnal hemoglobinuria study introduces a deeper knowledge of Gastroenterology. Hubert Schrezenmeier usually deals with Gastroenterology and limits it to topics linked to Hemolysis and Concomitant. His Antibody research incorporates elements of Blockade, Vaccination, Virology and Recombinant DNA.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

Peter Hillmen;Neal S. Young;Jörg Schubert;Robert A. Brodsky.
The New England Journal of Medicine (2006)

1148 Citations

Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.

Peter Hillmen;Petra Muus;Ulrich Dührsen;Antonio M. Risitano.
Blood (2007)

581 Citations

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

Robert A. Brodsky;Neal S. Young;Elisabetta Antonioli;Antonio M. Risitano.
Blood (2008)

574 Citations

T cell stimulation by staphylococcal enterotoxins. Clonally variable response and requirement for major histocompatibility complex class II molecules on accessory or target cells.

Bernhard Fleischer;Hubert Schrezenmeier.
Journal of Experimental Medicine (1988)

558 Citations

Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men.

Ernst Späth-Schwalbe;Kirsten Hansen;Frauke Schmidt;Hubert Schrezenmeier.
The Journal of Clinical Endocrinology and Metabolism (1998)

494 Citations

Treatment of Aplastic Anemia with Antilymphocyte Globulin and Methylprednisolone with or without Cyclosporine

Norbert Frickhofen;Joachim P. Kaltwasser;Hubert Schrezenmeier;Aruna Raghavachar.
The New England Journal of Medicine (1991)

468 Citations

Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia

Norbert Frickhofen;Hermann Heimpel;Joachim P. Kaltwasser;Hubert Schrezenmeier.
Blood (2003)

449 Citations

Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT).

Anna Locasciulli;Rosi Oneto;Andrea Bacigalupo;Gerard Socie.
Haematologica (2007)

390 Citations

CDC42 ACTIVITY REGULATES HEMATOPOIETIC STEM CELL AGING AND REJUVENATION

Maria Carolina Florian;Karin Dörr;Anja Niebel;Deidre Daria.
Cell Stem Cell (2012)

375 Citations

Mesenchymal stem cells for clinical application.

L. Sensebe;M. Krampera;Hubert Schrezenmeier;P. Bourin.
Vox Sanguinis (2010)

362 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Hubert Schrezenmeier

Neal S. Young

Neal S. Young

National Institutes of Health

Publications: 91

Hartmut Geiger

Hartmut Geiger

University of Ulm

Publications: 60

Judith C. W. Marsh

Judith C. W. Marsh

University of Cambridge

Publications: 58

Gérard Socié

Gérard Socié

Université Paris Cité

Publications: 55

Katharina Landfester

Katharina Landfester

Max Planck Institute for Polymer Research

Publications: 50

Jakob Passweg

Jakob Passweg

University Hospital of Basel

Publications: 48

Jaroslaw P. Maciejewski

Jaroslaw P. Maciejewski

Cleveland Clinic

Publications: 44

Volker Mailänder

Volker Mailänder

Max Planck Society

Publications: 42

Peter Hillmen

Peter Hillmen

St James's University Hospital

Publications: 39

Taroh Kinoshita

Taroh Kinoshita

Osaka University

Publications: 38

Halvard Bonig

Halvard Bonig

German Red Cross

Publications: 37

Erhard Seifried

Erhard Seifried

German Red Cross

Publications: 36

Seiji Kojima

Seiji Kojima

Nagoya University

Publications: 35

Andrea Bacigalupo

Andrea Bacigalupo

Catholic University of the Sacred Heart

Publications: 34

Ghulam J. Mufti

Ghulam J. Mufti

University of Cambridge

Publications: 30

H. Joachim Deeg

H. Joachim Deeg

Fred Hutchinson Cancer Research Center

Publications: 29

Something went wrong. Please try again later.